Results 151 to 160 of about 2,468 (182)

Idarucizumab

pharma-kritik, 2017
Dieses Medikament wirkt der Antikoagulation durch den direkten Thrombinhemmer Dabigatran entgegen. Sein praktischer Nutzen ist aber bisher nicht genügend dokumentiert. Da auch sein Nebenwirkungspotential noch nicht geklärt ist, kann die Verwendung dieses sehr teuren Mittels wohl am ehesten noch im Rahmen weiterer Studien verantwortet werden.
  +4 more sources

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection

International Journal of Stroke, 2017
BackgroundIdarucizumab is a monoclonal antibody fragment with high affinity for dabigatran that reverses its anticoagulant effects within minutes. It may exhibit the potential for patients under dabigatran therapy suffering ischemic stroke to regain ...
Pawel Kermer, Klaus Groschel, Peter Ringleb   +2 more
exaly   +3 more sources

Reversal of Dabigatran with Idarucizumab

Expert Review of Cardiovascular Therapy, 2016
The use of novel oral anticoagulants such as dabigatran has been increasing over the last five years. Indicated for use in the prevention of thromboembolic complications from non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolic disease, dabigatran is increasingly encountered clinically.
Neel R, Sodha, Frank W, Sellke
openaire   +2 more sources

Eluxadoline, Lesinurad, and Idarucizumab

Journal of the American Pharmacists Association, 2016
Irritable bowel syndrome (IBS) is estimated to affect 10% to 15% of adults in the United States. Some patients with IBS experience diarrhea as the most common manifestation (IBS-D), and others experience constipation as the most commonmanifestation (IBS-C).
Daniel A, Hussar, Maggie, Gandhi
openaire   +2 more sources

Idarucizumab (Praxbind) Formulary Review

Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine, 2016
Idarucizumab (Praxbind), a humanized monoclonal antibody fragment was granted accelerated approval from the Food and Drug Administration in October 2015 as the first agent to reverse the effects of a novel oral anticoagulant. The drug is indicated for dabigatran reversal in patients requiring emergency surgery/urgent procedures or with life-threatening
Jessica, Buchheit, Prabashni, Reddy, Jean M, Connors   +2 more
openaire   +2 more sources

Incomplete dabigatran reversal with idarucizumab

Clinical Toxicology, 2017
With increasing use of direct oral anticoagulants (DOACs), urgent reversal of these agents becomes a growing concern. Idarucizumab is a humanized monoclonal antibody fragment that specifically binds to dabigatran with higher affinity than thrombin, rapidly neutralizing its anticoagulant effect without increased risk of thrombosis.We describe two cases ...
Aaron P. Steele, Jin A. Lee, William E. Dager   +2 more
openaire   +2 more sources

Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation

Annals of Pharmacotherapy, 2016
Objective: To review clinical data on idarucizumab for the reversal of dabigatran-associated anticoagulation. Data Sources: Articles for this review were identified via PubMed using the MeSH term dabigatran combined with the keyword idarucizumab. Additional online searches via PubMed and Google Scholar were conducted for both prescribing and cost ...
Dinesh, Yogaratnam, Kristen, Ditch, Kristin, Medeiros, Cassandra, Doyno, Jeffrey J, Fong   +4 more
openaire   +2 more sources

Idarucizumab: First Global Approval

Drugs, 2015
Idarucizumab (Praxbind(®)) is a fully humanized, monoclonal antibody fragment developed by Boehringer Ingelheim as a specific antidote to reverse the anticoagulant effect of the direct oral thrombin inhibitor dabigatran etexilate (Pradaxa(®)). Idarucizumab received its first global approval, in the USA, in October 2015 for use in adult patients treated
openaire   +2 more sources

Idarucizumab

Reactions Weekly, 2023
openaire   +1 more source

Idarucizumab

Reactions Weekly, 2018
openaire   +2 more sources